Clinical trials
ATTR Amyloidosis clinical trials
Below are recruiting attr amyloidosis clinical trials, each written for real people, not researchers. We’re tracking 35 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07448623RecruitingPhase 1
Testing coramitug for ATTR amyloid heart disease
This study tests a new medication called coramitug to see if it can reduce abnormal protein deposits in the heart. You will have special PET/CT scans to measure how the drug affects these deposits.
GroningenAges 60 years+ - NCT06318260RecruitingPhase 1/Phase 2
Dobutamine for heart failure in wild-type ATTR amyloidosis
This trial tests whether dobutamine, a heart-strengthening medicine, can improve blood flow and symptoms in people with a specific type of amyloidosis that affects the heart and who are already on water pills.
AarhusAges 65 years+ - NCT04636684Recruiting
Study ATTR deposits in the aortic valve
This study looks at how common ATTR-related protein deposits are in the heart valve of people with age-related (degenerative) aortic stenosis. It may help doctors understand how important these deposits are and could guide future treatment decisions.
ToulouseAges 18–99 - NCT05776212Recruiting
Imaging study for certain heart amyloidosis types and heart thickening
This trial uses special heart imaging to better measure how amyloid deposits affect the heart in people with certain diagnoses. The goal is to understand which imaging signals match your disease and to see if this approach could help guide care.
GroningenAges 40 years+ - NCT07112066Recruiting
Heart imaging study for ATTR amyloidosis patients
This study uses heart imaging to track disease progression in people with ATTR cardiac amyloidosis who are about to start tafamidis treatment. It aims to understand how the disease changes over time.
Zurich, Canton of ZurichAges Any age - NCT05098665Recruiting
Home monitoring to help prevent hospital stays for ATTR heart disease
This trial tests whether using home weight/health tracking can help people with ATTR cardiomyopathy avoid going to the hospital. It may help by catching fluid build-up or worsening earlier so treatment can be adjusted sooner.
London, LondonAges 18 years+ - NCT05577819Recruiting
Screening for ATTR heart amyloid in older HFpEF patients
This study looks at how often a specific heart condition (ATTR amyloid) occurs in people age 65+ who have HFpEF. It also tries to predict who might have it, using a special heart scan, and may help your care team identify it earlier.
Boston, MassachusettsAges 65 years+ - NCT05697861Enrolling by invitation
Follow-up study for people previously treated with NTLA-2001
This study checks how people are doing long-term after receiving NTLA-2001 in an Intellia clinical trial. If you previously took part and agree to be followed, this may help the researchers understand lasting safety and effects.
ParisAges 18 years+ - NCT07215715Recruiting
Heart ultrasound study for older adults with heart failure
This study uses a special ultrasound to measure heart stiffness in people 60 and older who have heart failure with preserved or mildly reduced pumping function, with or without a condition called ATTR amyloidosis (a protein buildup in the heart). It also includes healthy controls.
Boston, MassachusettsAges 60 years+ - NCT07358078Recruiting
Long-term study of ATTR-CM patients on vutrisiran or other approved therapies
This study observes people with ATTR-CM (a heart condition caused by a protein called transthyretin) who are starting treatment with vutrisiran or another approved therapy. It aims to understand how the disease progresses and how treatments work in real life.
Naples, FloridaAges 18 years+ - NCT07306949RecruitingPhase 4
Acoramidis for transthyretin cardiac amyloidosis
This trial tests a new medicine called acoramidis for people with a heart condition caused by a protein called transthyretin. It includes people who are newly diagnosed or who are already taking another drug (tafamidis) and may benefit from switching. The goal is to see how well acoramidis works and how it affects heart-related measures.
Bunkyō CityAges 18–100
Hear when a new ATTR Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for attr amyloidosis?
- Yes. Clin2 currently lists 35 recruiting attr amyloidosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a attr amyloidosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a attr amyloidosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.